天眼查App显示,2025年5月16日,“一种靶向蛋白调节剂的化合物及其应用”正式进入专利公布阶段。申请人为上海医药集团股份有限公司,该项生物医药专利涉及KRAS突变体抑制或蛋白降解相关技术领域。据专利信息显示,该发明对KRAS突变体具有良好的抑制作用或蛋白降解作用,实现了显著优化的技术效果。发明人为李迪、楼江松、夏广新、马星。“本发明公开了一种靶向蛋白调节剂的化合物及其应用。该化合物为如式I所示...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.